Compare Recursion Pharmaceuticals Inc (RXRX) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sirius XM Holdings Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Sirius XM Holdings Inc trades at $30.18 (market cap $10.30B). The key difference: Sirius XM Holdings Inc is far larger — about 6.7× Recursion Pharmaceuticals Inc's market cap, and Sirius XM Holdings Inc pays a 3.53% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SIRI | |
|---|---|---|
Market Cap | $1.53B | $10.30B |
Sector | Health | Media |
52-Week High | $6.79 | $31.22 |
52-Week Low | $2.84 | $19.92 |
Enterprise Value | $946.50M | $19.97B |
Dividend Yield | — | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Sirius XM (SIRI) trades at $30.29, down 0.98% on the day, with a bullish technical signal from moving averages and recent earnings beats. The stock shows solid fundamentals with a P/E of 12.97, net income margin of 9.86%, and a recent dividend payment. Revenue stabilized around $8.6B in 2025 after a dip in 2024, while debt-to-asset ratio improved to 35.63%.
Outlook is positive with analyst consensus at Buy (58% of ratings) and a $30.71 price target, though risks include competitive pressures and reliance on subscription growth. The YouTube ad partnership and inclusion in the S&P MidCap 400 provide catalysts, but investors should monitor Q2 2026 earnings due July 30 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
